Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 3/20 | 0.49 |
| ▸ | PPARA | Q07869 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDH1 | O75874 | 7/20 | 0.42 |
| ▸ | IL6ST | P40189 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.40 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL291952 | 1.00 | NAAA (0.49) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL237075 | 1.00 | NAAA (0.49) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL6244705 | 0.99 | NAAA (0.48) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL292752 | 0.89 | NAAA (0.53) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL292751 | 0.89 | NAAA (0.53) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL2207671 | 0.89 | NAAA (0.53) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL9683998 | 0.89 | NAAA (0.41) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL9683994 | 0.89 | NAAA (0.41) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL1750169 | 0.88 | ALDH1A1 (0.55) | NAAAPPARAFAAHALDH1A1IDH1 | |
| SCHEMBL1750168 | 0.88 | ALDH1A1 (0.55) | NAAAPPARAFAAHALDH1A1IDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 354 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024040267-A2 | DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF | MITOKININ, INC. (US) | 2024-02-22 | — | — | WO | claimed |
| WO-2005028486-A1 | METHODS OF REFINING SILANE COMPOUNDS | HONEYWELL INTERNATIONAL INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050059835-A1 | Methods of refining silane compounds | HONEYWELL INTERNATIONAL INC. (US) | 2005-03-17 | — | — | US | claimed |
| US-6340751-B1 | REACTION OF IMIDAZOLONE WITH AMIDE AND MAGNESIUM COMPOUND | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2002-01-22 | — | — | US | claimed |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | LG CHEM, LTD. (KR) | 2026-05-26 | — | — | US | disclosed |
| US-12570618-B2 | Compound, production method therefor, and pharmaceutical composition | TOKYO UNIVERSITY OF SCIENCE FOUNDATION (JP) | 2026-03-10 | — | — | US | disclosed |
| EP-4293013-B1 | NOVEL COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION | UNIV TOKYO SCIENCE FOUND (JP) | 2025-08-20 | — | — | EP | disclosed |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-07-08 | — | — | US | disclosed |
| EP-4578451-A2 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | Novartis AG (CH) | 2025-07-02 | — | — | EP | disclosed |
| EP-4558543-A2 | BIO-RENEWABLE POLYMERS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4214210-B1 | COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS | NOVARTIS AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | EXELIXIS INC (US) | 2025-03-27 | — | — | US | disclosed |
| WO-1997024117-A1 | SUBSTITUTED (ARYL, HETEROARYL, ARYLMETHYL OR HETEROARYLMETHYL) HYDROXAMIC ACID COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5646143-A | FOR TREATING A VARIETY OF CONDITIONS | CIBA-GEIGY CORPORATION (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627182-A | RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS | CIBA GEIGY CORPORATION (US) | 1997-05-06 | — | — | US | disclosed |
| US-5559111-A | HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren | CIBA-GEIGY CORPORATION (US) | 1996-09-24 | — | — | US | disclosed |
| US-5478826-A | Fungicides for human, animal and plants | J. URIACH & CIA. S.A. (ES) | 1995-12-26 | — | — | US | disclosed |
| US-5332807-A | Process of producing 8A- and 9A-azalide antibiotics | MERCK & CO., INC. (US) | 1994-07-26 | — | — | US | disclosed |
| WO-1993005011-A1 | NOVEL IMMUNOSUPPRESSANTS | SANDOZ LTD. (CH) | 1993-03-18 | — | — | WO | disclosed |
| US-5132457-A | Stereospecific synthesis of 2(R)-2-methyl-3-dimethylamino-propiophenone (d-DAMP) | MALLINCKRODT SPECIALTY CHEMICALS COMPANY (US) | 1992-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059835-A1 | Methods of refining silane compounds | HDAC10, HDAC1, HDAC11 | NAAA 893/4885PPARA 2252/4885FAAH 3227/4885 |
| US-12351559-B2 | Benzoimidazol benzomidazol-1,2-yl amides as Kv7 channel activators | KCNA7, KCNJ2, KCNK17 | NAAA 1634/4885PPARA 1503/4885FAAH 2779/4885 |
| US-20250100966-A1 | MEK INHIBITORS AND METHODS OF THEIR USE | BRAF, NRAS, KRAS | NAAA 2576/4885PPARA 2908/4885FAAH 1940/4885 |
| US-12570618-B2 | Compound, production method therefor, and pharmaceutical composition | DHCR7, NR1H3, NR1H2 | NAAA 3647/4885PPARA 1112/4885FAAH 1416/4885 |
| US-12637440-B2 | Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof | DGAT2, DGAT1, DLAT | NAAA 140/4885PPARA 305/4885FAAH 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.